Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Not all cancers are equal: uneven access to glioma clinical trials in Europe.

Acta neurologica Belgica·2026

Same author

Prescription of Psychotropic Drugs for Chronic Insomnia in Primary Care.

Journal of sleep research·2026

Same author

Advances in the management of metastatic lobular breast cancer: Current evidence and emerging treatments.

Seminars in oncology·2026

Same author

Antibiotic Use in the Community in Spain: A National Surveillance System Within the Framework of the Spanish Action Plan on Antimicrobial Resistance.

Antibiotics (Basel, Switzerland)·2025

Same author

Long-Term Effectiveness of Acetylsalicylic Acid in Primary Prevention of Cardiovascular Diseases and Mortality in Patients at High Risk, a Retrospective Cohort Study-The JOANA Study.

Journal of clinical medicine·2025

Same author

Absolute impact of lipid levels on coronary heart disease in a real-world primary prevention cohort of 730,236 people.

American journal of preventive cardiology·2025

Search research articles

Related Experiment Video

Updated: Sep 16, 2025

Modeling Brain Metastasis Via Tail-Vein Injection of Inflammatory Breast Cancer Cells

Modeling Brain Metastasis Via Tail-Vein Injection of Inflammatory Breast Cancer Cells

Published on: February 4, 2021

Antiplatelet Therapy Mitigates Brain Metastasis Risk in Non-Small Cell Lung Cancer: Insights from a Comprehensive

Carla Martín-Abreu¹, María García-Gil², Margarita Méndez-Monge²

¹Department of Medical Oncology, Hospital Universitario de Canarias, 38320 La Laguna, Spain.

|July 12, 2025

Summary

Antiplatelet therapy, particularly aspirin, is associated with a significantly lower risk of brain metastases in non-small cell lung cancer (NSCLC) patients. This real-world study suggests a stage-dependent benefit, supporting further research into antiplatelet use for NSCLC management.

Keywords:

antiplatelet therapy brain metastases non-small cell lung cancer (NSCLC)platelet–tumor interaction real-world evidence

More Related Videos

Modeling Brain Metastasis by Internal Carotid Artery Injection of Cancer Cells

Modeling Brain Metastasis by Internal Carotid Artery Injection of Cancer Cells

Published on: August 2, 2022

Modeling Brain Metastases Through Intracranial Injection and Magnetic Resonance Imaging

Modeling Brain Metastases Through Intracranial Injection and Magnetic Resonance Imaging

Published on: June 7, 2020

Related Experiment Videos

Last Updated: Sep 16, 2025

Modeling Brain Metastasis Via Tail-Vein Injection of Inflammatory Breast Cancer Cells

Modeling Brain Metastasis Via Tail-Vein Injection of Inflammatory Breast Cancer Cells

Published on: February 4, 2021

Modeling Brain Metastasis by Internal Carotid Artery Injection of Cancer Cells

Modeling Brain Metastasis by Internal Carotid Artery Injection of Cancer Cells

Published on: August 2, 2022

Modeling Brain Metastases Through Intracranial Injection and Magnetic Resonance Imaging

Modeling Brain Metastases Through Intracranial Injection and Magnetic Resonance Imaging

Published on: June 7, 2020

Area of Science:

Oncology
Pharmacology
Translational Research

Background:

Brain metastases are a severe complication of non-small cell lung cancer (NSCLC), impacting patient prognosis and quality of life.
The role of platelets in cancer progression and the effect of antiplatelet therapy on NSCLC brain metastasis remain underexplored.

Purpose of the Study:

To evaluate the correlation between antiplatelet agent exposure and the incidence of brain metastases in NSCLC patients.
To investigate the potential protective effect of antiplatelet therapy against brain metastasis development in NSCLC.

Main Methods:

Retrospective observational study analyzing data from 650 NSCLC patients over four years.
Evaluation of prior or subsequent exposure to antiplatelet agents and its association with brain metastasis incidence.

Main Results:

Antiplatelet therapy users (predominantly aspirin) showed a significantly lower risk of brain metastases (6.9% vs. 20.0%, p < 0.001), especially in advanced stages.
Antiplatelet use was linked to a longer time to metastasis development (77.5 vs. 62.6 months, p < 0.001) and improved progression-free survival.
Reduced incidence of brain metastases at diagnosis was observed in patients on antiplatelets prior to diagnosis (3.9% vs. 12.1%, p = 0.014).

Conclusions:

This study provides real-world evidence of a consistent, stage-dependent association between antiplatelet use and reduced brain metastatic burden in NSCLC.
Findings suggest antiplatelet agents may interfere with metastatic spread mechanisms like immune evasion and premetastatic niche formation.
The research offers a novel clinical perspective supporting further investigation into integrating antiplatelet therapy into NSCLC management strategies.